- Home
- CRMD
CRMD
CorMedix Inc.
as 11-24-2025 9:40am EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 876.7M | IPO Year: | 2010 |
| Target Price: | $17.43 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.60 - $17.43 | Next Earning Date: | 11-12-2025 |
| Revenue: | $214,303,672 | Revenue Growth: | 1647.67% |
| Revenue Growth (this year): | 565.64% | Revenue Growth (next year): | 46.09% |
Stock Insider Trading Activity of CorMedix Inc. (CRMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dillione Janet | CRMD | Director | Nov 14 '25 | Sell | $11.42 | 30,000 | $342,600.00 | 48,473 | |
| Kaplan Myron | CRMD | Director | Oct 23 '25 | Buy | $11.02 | 25,000 | $275,500.00 | 201,034 | |
| DUNTON ALAN W | CRMD | Director | Sep 12 '25 | Sell | $13.13 | 10,000 | $131,300.00 | 40,250 | |
| Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 11 '25 | Sell | $13.08 | 41,121 | $537,862.68 | 176,990 | |
| Zelnick Kaufman Beth | CRMD | Chief Legal Officer | Sep 9 '25 | Sell | $13.12 | 50,000 | $670,264.00 | 180,418 | |
| Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 9 '25 | Sell | $13.51 | 12,876 | $173,954.76 | 176,990 |
Latest CorMedix Inc. News
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
Zacks
18 days ago
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
Zacks
18 days ago
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Zacks
18 days ago
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Zacks
19 days ago
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
Zacks
19 days ago
Bet on 5 Top-Ranked Stocks With Rising P/E
Zacks
20 days ago
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
Zacks
20 days ago
New Strong Buy Stocks for November 4th
Simply Wall St.
21 days ago
Could the FDA Approval Spark a New Chapter for CorMedix in 2025?
Compare CRMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.